Key Takeaway: Taysha Gene Therapies has completed dosing in the REVEAL and ASPIRE trials for TSHA-102, targeting Rett syndrome. The company anticipates reporting topline data from a six-month interim analysis and receiving FDA feedback on the Biologics License Application submission pathway in the first half of 2027. TSHA-102 has shown good tolerance among participants.
Market Sentiment Analysis
POSITIVE FACTORS
Completed dosing in pivotal trials for TSHA-102.
Expecting topline data and FDA feedback in 1H 2027.
TSHA-102 is generally well tolerated.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+67%
120-day peak, hindsight
Typical move
1.7%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
TSHA-101
Phase 1 · Infantile GM2 Gangliosidosis (Disorder)
Full Press Release Details
Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027 TSHA-102 continues to be generally well tolerated with no severe
Frequently Asked Questions
What trials has Taysha completed for TSHA-102?
Taysha has completed dosing in the REVEAL and ASPIRE trials for TSHA-102.
When will Taysha report topline data?
Topline data from the six-month interim analysis is expected in 1H 2027.
How is TSHA-102 tolerated among participants?
TSHA-102 has been generally well tolerated with no severe adverse events reported.